Advertisement

 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links

advertisement.gif (61x7 -- 0 bytes)

   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 

 

 

Back to index

Cancer Chemotherapy Regimen for Esophageal Cancer


 FAP                                                 esophagus(54)
 _________________________________________________________________
  fluorouracil.... 600 mg/sqm IV days 1 and 8.
  adriamycin...... 30 mg/sqm IV day 1.
  cisplatin....... 75 mg/sqm IV day 1 with hydration and mannitol 
                   diuresis.
  FREQUENCY....... Repeat courses every 4 weeks as tolerated.

  reference...
    Gisselbrecht C.  Calvo F.  Mignot L.  Pujade E.  Bouvry M.  
    Danne O. Belpomme D.  Marty M. Fluorouracil (F), Adriamycin 
    (A), and cisplatin (P) (FAP): combination chemotherapy of 
    advanced esophageal carcinoma. Cancer.  52(6):974-7, 1983 Sep 
    15. 
  abstract...
    Twenty-one patients with advanced epidermoid carcinoma of the 
    esophagus were treated with a combination of 5-fluorouracil 
    (F) 600 mg/m2 day 1 and day 8; Adriamycin (A) 30 mg/m2 day 1; 
    and cisplatin (P) 75 mg/m2 day 1 (FAP) with hydration and 
    mannitol-induced diuresis. Each course was repeated every 4 
    weeks. All 21 patients are evaluable for response: 7 patients 
    had an objective response (33%). Two of these responses were 
    complete remissions according to negative endoscopic and 
    pathologic results; five patients had a partial response; all 
    7 responding patients had metastasis prior to treatment. 
    Median survival of the 21 patients was 8 months. Median 
    survival of 9 months for responders is superior to 4.5 months 
    for nonresponders. No severe myelosuppression or 
    nephrotoxicity was observed. This FAP regimen is useful in the 
    treatment of advanced esophageal tumors. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2007 The Doctors Lounge. All rights reserved.